Trial of Proteinuria Reduction Effect of Losartan/Hydrochlorothiazide Therapy to Chronic Kidney Disease with Hypertension

Trial of Proteinuria Reduction Effect of Losartan/Hydrochlorothiazide Therapy to Chronic Kidney Disease with Hypertension - Trial of Proteinuria Reduction Effect of Losartan/Hydrochlorothiazide to CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001643

Enrollment

120

Registered

2009-01-19

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease patients with hypertension

Interventions

ARB/hydrochlorothiazide combination drug ARB

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.All patients have hypertension (sBP >130, dBP >80) 2.All patients fulfilled the inclusion criteria of a stable proteinuria Up/Ucr >0.3. 3.All patients have CKD, and eGFR >15mL/min/1.73m2. 4. Age between 20 and 75yr are included.

Exclusion criteria

Exclusion criteria: Patients with uncontrolled hypertension, serum patassium >5.5 mEq/L, cardiovascular disease (myocardial infarction, unstable angina, stroke within last 3 months), pregnancy,lactation,nephrotic syndrome (serum Alb <2g/dl), frequent users of diuretics are excluded.

Design outcomes

Primary

Measure	Time frame
The primary end point is change in the Up:Ucr ratio from baseline to month 12.	—

Countries

Japan

Contacts

Public ContactKiichiro Fujisaki

Kyushu University Hospital Kidney Care Unit

092-642-5843

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026